Cord blood cells join forces with drug to fight transplant complication

NCT ID NCT04744116

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This early study tests whether adding special cells from donated umbilical cord blood (called mesenchymal stromal cells) to the drug ruxolitinib can help control severe graft-versus-host disease (GVHD) that hasn't improved with steroids. GVHD is a serious complication where donor immune cells attack the patient's body after a stem cell transplant. The trial will enroll 24 people aged 12 to 80 and compare the combination therapy against ruxolitinib alone, looking at response rates and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
cord blood tissue-derived mesenchymal stromal cells (cb-MSCs) combined with ruxolitinib
What this could lead to
If it works, this could point toward a better treatment for severe graft-versus-host disease that doesn't respond to steroids.
What could go wrong
This is a very early, small pilot study with only 24 people, so results may not apply widely. There is also a risk of side effects from the cell infusion or the drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • M D Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.